Senate Funding Bills Fail to Block Controversial Trump-Era OMB Rule
The Impending Shift in Federal Grant Oversight
Following the conclusion of the midterm elections, the U.S. Congress has entered a critical transition period. With numerous lawmakers serving as “lame ducks,” the legislative body faces an urgent decision regarding a controversial proposal from the White House Office of Management and Budget (OMB). This regulation, slated for potential implementation on December 11, threatens to fundamentally alter the landscape of federal funding. If enacted, it would grant the Trump administration and its political appointees unprecedented authority over more than $1 trillion in annual federal contracts and grants.
Senate Appropriations Bills Omit Safeguards
Recent disclosures from the Senate Appropriations Committee regarding fiscal year 2027 funding bills suggest that the chamber is unlikely to intervene. The legislative packages—including the Financial Services and General Government bill, which directly funds the OMB—are entirely devoid of language intended to delay or nullify the proposed rule. This legislative silence effectively clears a path for the administration to gain significant power, potentially allowing political appointees to bypass scientific peer review and terminate federal funding streams without warning or substantive justification.
Public Outcry and the Call for Congressional Action
The lack of legislative pushback stands in stark contrast to the intense opposition voiced by health, research, and patient advocacy groups earlier this year. During the public comment period, thousands of stakeholders warned that politicizing the grant process could transform vital funding from the National Institutes of Health (NIH), the National Science Foundation (NSF), and other agencies into political leverage, undermining their core mission of public benefit.
The December 11 Deadline
While Congress previously passed a continuing resolution to extend FY 2026 funding levels through December 11—thereby delaying the OMB rule's implementation—this was merely a temporary reprieve. As the deadline approaches, the administration's history of abruptly terminating NIH grants and withholding funds from universities remains a point of contention. Russ Paulsen, CEO of Research!America, expressed deep concern, stating, “It is deeply troubling that none of the Senate bills would block a proposed federal regulation that would allow bureaucrats to terminate research grants and clinical trials at any time for political reasons.”
The Lame-Duck Dilemma
The inaction of the current Senate is particularly notable given the composition of the Appropriations Committee, currently led by outgoing Senator Susan Collins. With the Senate set to transition from a 53-47 Republican majority to a 56-44 Democratic majority in January 2027, the current legislative session is defined by a significant number of members who will not return. Despite their reduced political capital, these lawmakers retain the authority to shape federal policy in the final weeks of the year. The question remains whether this outgoing Congress will address the OMB rule or allow a significant shift in executive power to take effect before the new term begins.